Renhuang Pharmaceuticals' Siberian Ginseng capsule patent application passes preliminary SIPO review

Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that on March 28, 2010, the Company's patent application for its proprietary Siberian Ginseng (Acanthopanax) Total Glucosides Total Flavonoids Soft Capsules and related formulation method passed a preliminary review conducted by the State Intellectual Property Office of the People's Republic of China ("SIPO").

Renhuang's all natural, plant-based Siberian Ginseng Total Glucosides Total Flavonoids Soft Capsules are oral medication being developed to treat cardiovascular and cerebrovascular diseases and provide nerve regulation and leverages the Company's proprietary formulations. The Company's patent application will now enter a comprehensive examination phase by the SIPO, which is typically a two year process. If approved, the patent is expected to provide market exclusivity for a period of 16 to 18 years from the date of the patent approval.

"Passing the preliminary review by the SIPO is an important step and puts the Company on the right track towards eventual patent application approval for the drug and related formulation method," said Mr. Shaoming Li, Chairman and CEO of Renhuang Pharmaceuticals, Inc. "Securing patent protection for our proprietary products and unique formulation method is a critical component of our long-term growth strategy. This patent, if issued, will help to reinforce our competitive advantage in the high-growth market for Siberian Ginseng Products and strengthen our future revenue growth opportunities."